President Trump recently criticized the FDA approval process as "slow and burdensome" but failed to offer up specific plans for reform. If FDA standards were to be altered, the market could see an avalanche of new drugs and treatments. TheStreet's Adam Feuerstein compiled the "Gnarly Nine" companies that could be interesting to watch as the FDA enters the Trump era. 

  1. Alkermes (ALKS)
  2. CytRX (CYTR)

  3. Dynavax Technologies (DVAX)

  4. Intra-Cellular Therapies (ITCI)

  5. Novan (NOVN)

  6. Portola Pharmaceuticals (PTLA)

  7. PTC Therapeutics (PTCT)

  8. Rigel Pharmaceuticals (RIGL)

  9. TG Therapeutics (TGTX)

READ THE FULL STORY HERE: These 'Gnarly 9' Biotechs Will Test the FDA's Mettle
This article was written by a staff member of TheStreet.

If you liked this article you might like

The 6 Medications Being Used to Tackle the Opioid Epidemic

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Verizon, Randgold Resources, Bank of America: 'Mad Money' Lightning Round